Milestone Pharmaceuticals Says FDA Accepted for Review Cardamyst Nasal Spray Resubmission

MT Newswires Live
07/11

Milestone Pharmaceuticals (MIST) said Friday the US Food and Drug Administration has accepted for review its response to issues raised in the regulator's complete response letter for Cardamyst nasal spray.

The FDA has set a target action date of Dec. 13.

Cardamyst nasal spray is a novel investigational therapy for the treatment of acute episodes of paroxysmal supraventricular tachycardia, a type of abnormal heart rhythm.

Shares of the company were down ore than 24% in Friday premarket activity.

Price: 1.94, Change: -0.62, Percent Change: -24.22

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10